Virtual Event Coverage

The Wall Street Investor Forum

September 10, 2020 - Virtual Format

The Wall Street Investor Forum's 28th Annual Investor Forum is exclusively virtual. Designed to be a vibrant nexus of financial intermediation, facilitating the flow of capital to its most productive uses, the web-hosted nature of this conference avoids the geographic limitations associated with physical events to offer presenting companies opportunity for much wider exposure while avoiding the significant costs of physical attendance. The Wall Street Investor Forum has been linking ideas and capital since 1989. The conference series made history after becoming the first to do a live webcast presenting 100 NYSE/NASDAQ companies at the New York Hilton. Since inception, the forum has sponsored 85 conferences in New York, Boston and London — attended by analysts and portfolio managers from more than 3,000 different institutions — for public corporations.

For more information visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) develops novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM, which Reata conducted in 2006. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. For more information, visit the company's website at
Webcast Registration

Helius Medical Technologies (NASDAQ: HSDT)

Helius Medical Technologies (NASDAQ: HSDT) is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the Portable Neuromodulation Stimulator (PoNS™). Helius was formed as a joint venture between scientists and commercialization experts to address the enormous implications of a massive unmet medical need in the market. For more information, visit the company's website at
Webcast Registration

Exro Technologies Inc. (OTCQB: EXROF)

Exro Technologies Inc. (OTCQB: EXROF) is a clean tech company that has developed a new class of control technology for electric powertrains. Exro's advanced motor control technology, 'Coil Driver', expands the capabilities of electric motors and powertrains. The limitations of traditional electric machines and power technology have become more apparent. In many increasingly prominent applications, traditional methods cannot meet the required performance. Exro offers a new solution for system optimization through implementation of the technology, which can yield the following results: increased drive cycle efficiency, reduced system volume, reduced weight and expanded torque and speed capabilities. For more information, visit the company's website at
Webcast Registration

LexaGene Holdings Inc. (OTCQB: LXXGF)

LexaGene Holdings Inc. (OTCQB: LXXGF) is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics and food safety, as well as for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press 'go'. The LX Analyzer delivers excellent sensitivity, specificity and breadth of detection and can return results in about one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information, visit the company's website at
Webcast Registration

Thunderbird (TSX-V: TBRD)

Through Atomic Cartoons (Kids & Family) and Great Pacific Media (Factual & Scripted), Thunderbird (TSX-V: TBRD) is a leader in developing and producing family entertainment and sold to key buyers including Netflix, HBO Max, Nickelodeon, Discovery Channel, Apple TV+, Disney+, NBCUniversal, CBC and traditional broadcast and cable channels in >250 territories globally. Their programs air daily in 40 different languages and include hits such as Beat Bugs, Kim's Convenience, Highway Thru Hell, Blade Runner 2049, Hello Ninja and the Peabody Award winning, Molly of Denali. Thunderbird is a rapidly growing and highly profitable, multi-platform business with FY2019 revenue of $61.5M and FY2019 AEBITDA in of $11.2M. They are pursuing an aggressive organic growth strategy through investment in owned-IP as well as strategic M&A. Their substantial library funds development of proprietary IP productions and continues to attract revenues past its completion date. For more information, visit the company's website at
Webcast Registration

TONIX Pharmaceuticals Inc. (NASDAQ: TNXP)

Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. For more information, visit the company's website at
Webcast Registration

Haynes International Inc. (NASDAQ: HAYN)

Haynes International Inc. (NASDAQ: HAYN) is a leading developer, manufacturer and marketer of technologically advanced, high-performance alloys, primarily for use in the aerospace, industrial gas turbine and chemical processing industries. Haynes International is one of the world's largest developers, manufacturers and distributors of high-performance nickel- and cobalt-based alloys for use in high-temperature and corrosion applications. For more information, visit the company's website at
Webcast Registration

Silence Therapeutics (OTC: SLNCF)

Silence Therapeutics PLC (OTC: SLNCF) is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi, is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial, and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations. For more information, visit the company's website at
Webcast Registration

Trxade Group Inc. (NASDAQ: MEDS)

Trxade Group Inc. (NASDAQ: MEDS) is an integrated drug-procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states, with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: the Trxade B2B trading platform, with 11,725 registered pharmacies; Integra Pharma Solutions, Trxade Group's virtual wholesale division; the Bonum Health platform, offering affordable telehealth services; and the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For more information, visit the company's website at
Webcast Registration

Sierra Metals Inc. (NYSE: SMTS)

Sierra Metals Inc. (NYSE: SMTS) is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new, key discoveries and still has many more exciting brownfield exploration opportunities that are within close proximity to the existing mines in Peru and Mexico. Additionally, the company has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential. For more information, visit the company's website at
Webcast Registration

Aptorum Group Ltd. (NASDAQ: APM)

Aptorum Group Ltd. (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group's current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women's health supplement, dioscorea opposita bioactive nutraceutical tablets, marketed under the brand name NativusWell®. For more information, visit the company's website at
Webcast Registration

Artesian Resources Corp. (NASDAQ: ARTNA)

Artesian Resources Corp. (NASDAQ: ARTNA) operates as a holding company of wholly owned subsidiaries, offering water, wastewater and related services on the Delmarva Peninsula. Artesian Water Company, the principal subsidiary, is the oldest and largest regulated water utility on the Delmarva Peninsula, with offices in Newark and Milton. It has provided water service since 1905. Artesian supplies 8.3 billion gallons of water per year through 1,331 miles of water main to approximately a third of all Delaware residents. For more information, visit the company's website at
Webcast Registration

AIM ImmunoTech Inc. (NYSE: AIM)

AIM ImmunoTech Inc. (NYSE: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system. For more information, visit the company's website at
Webcast Registration

Capstone Turbine Corp. (NASDAQ: CPST)

Capstone Turbine Corp. (NASDAQ: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via its direct sales team, as well as its global distribution network. Capstone provides scalable solutions from 30 kW to 10 MW that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects. To date, Capstone has shipped nearly 10,000 units to 83 countries; in FY20, the company saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon. For customers with limited capital or short-term needs, Capstone offers rental systems. For more information, visit the company's website at
Webcast Registration

RedHill Biopharma Ltd. (NASDAQ: RDHL)

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19. For more information, visit the company's website at
Webcast Registration

Let's get started.

Interested in a live, online demonstration? Schedule a date and time that works for you.

Schedule a LIVE Demo

Questions about IBN and our solutions? Call or send us an email.

(310) 299-1717